Skip to main content

Cookies on the NHS England website

We’ve put some small files called cookies on your device to make our site work.

We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.

Let us know if this is OK. We’ll use a cookie to save your choice. You canĀ read more about our cookies before you choose.

 

Your feedback matters and will make a difference. Help us understand your digital experience by taking our 10 minute survey. Your responses are completely anonymous. Start the survey.

  • Home
  • News
  • Publications
  • Statistics
  • Blogs
  • Events
  • Contact us
NHS England
  • About us
  • Our work
  • Commissioning
  • Get involved

Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Document first published:
9 July 2020
Page updated:
2 August 2021
Topic:
Commissioning, Medicine, Specialised commissioning
Publication type:
Policy or strategy

Infliximab will be available as a treatment option through routine commissioning for refractory or progressive neurosarcoidosis within the criteria set out in this document.

Document

Clinical Commissioning Policy: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical Commissioning Policy: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 269 KB
  • 10 pages

Document

Clinical panel report June 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical panel report June 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 35 KB
  • 3 pages

Document

Clinical panel report February 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical panel report February 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 25 KB
  • 1 pages

Document

Consultation report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Consultation report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 41 KB
  • 3 pages

Document

CPAG summary report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

CPAG summary report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 58 KB
  • 6 pages

Document

Evidence review: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Evidence review: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 449 KB
  • 39 pages

Document

Stakeholder-engagement-report-refractory-or-progressive-neurosarcoidosis-(adults-and-post-pubescent-children)

Stakeholder-engagement-report-refractory-or-progressive-neurosarcoidosis-(adults-and-post-pubescent-children)

  • PDF
  • 39 KB
  • 3 pages
  • Terms and conditions
  • Privacy and cookies
  • Social media moderation
  • Website feedback
  • Accessibility statement
  • Open Government Licence v3.0
  • Sign up to our email bulletins
  • Follow us on X
  • Follow us on Facebook
  • Find us on Instagram
  • Visit us on LinkedIn
  • Watch videos on YouTube
NHS website